Urology Austin, PLLC
Welcome,         Profile    Billing    Logout  
 1 Trial 
45 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Preston, Mark
NCT03216525: Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Recruiting
3
136
US
Alvimopan, Entereg, Placebo
Brigham and Women's Hospital, Merck Sharp & Dohme LLC
Bladder Cancer
12/23
06/24
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
BRIDGE, NCT05538663: Intravesical BCG vs GEMDOCE in NMIBC

Recruiting
3
870
US
Gemcitabine, GEMZAR, Docetaxel, Taxotere, Bacillus Calmette Guerin, BCG
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Non-muscle-invasive Bladder Cancer
11/29
10/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
NCT05399004: Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

Completed
N/A
34
NA
Survey Administration
Mayo Clinic, National Cancer Institute (NCI)
Bladder Carcinoma
06/24
06/24
NCT05918263: Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Recruiting
N/A
68
US
High-Intensity Interval Training Exercise Program
Dana-Farber Cancer Institute, Prostate Cancer Foundation
Prostate Cancer, Prostatic Neoplasms
03/26
03/27
Kates, Max
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
GEMDOCE, NCT04386746: Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Active, not recruiting
2
27
US
Gemcitabine, Gemzar, Docetaxel, Taxotere
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Carcinoma Bladder, Bladder Cancer
10/22
11/25
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1
51
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
NCT05399004: Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

Completed
N/A
34
NA
Survey Administration
Mayo Clinic, National Cancer Institute (NCI)
Bladder Carcinoma
06/24
06/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Dickstein, Rian
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1
24
US
ZH9
Prokarium Ltd
NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
06/25
07/27
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
uTRACT, NCT05874921: Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Recruiting
N/A
400
US
Jelmyto (mitomycin) for pyelocalyceal solution, Jelmyto, UGN-101
UroGen Pharma Ltd.
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
04/26
01/28
Mazzarella, Brian
ARID II, NCT06873581: Pivotal Study of Voro Urologic Scaffold

Recruiting
3
266
US
Voro Urologic Scaffold
Levee Medical, Inc.
Radical Prostatectomy, Stress Urinary Incontinence (SUI)
02/27
02/27
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated
N/A
3
US
NanoTherm Ablation
MagForce USA
Prostate Cancer
07/23
07/23
NCT05186740: ProVee Urethral Expander System IDE Study (ProVIDE)

Active, not recruiting
N/A
221
Europe, Canada, US
ProVee Urethral Expander System, ProVee Expander, ProVee, Urethral Access Sheath
ProVerum Medical
Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms
03/24
12/28
NCT06236802: ProVIDE II Bridging Study

Active, not recruiting
N/A
40
Europe, US
ProVee device, ProVee Expander, ProVee
ProVerum Medical
BPH With Symptomatic Lower Urinary Tract Symptoms
09/24
06/29
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting
N/A
120
Europe, US
UroLift, Rezum
NeoTract, Inc.
Benign Prostatic Hyperplasia
05/25
12/25
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Santoyo, Jose
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting
1/2
75
US
STM-416
SURGE Therapeutics
Non-muscle-invasive Bladder Cancer
12/25
12/25
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
RELIEF, NCT05512039: Reduced-dose Botox for Urgency Incontinence Among Elder Females

Recruiting
1/2
376
US
Botox 50 Unit Injection, OnabotulinumtoxinA 50 Unit Injection, Botox 100 Unit Injection, OnabotulinumtoxinA 100 Unit
Dartmouth-Hitchcock Medical Center, Patient-Centered Outcomes Research Institute, Dartmouth College, University of Alabama at Birmingham, University of Pittsburgh, University of Texas, Kaiser Permanente, Oregon Health and Science University, Stanford University, University of Connecticut, University of Nebraska
Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
09/26
01/27
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

Completed
N/A
121
US
Irreversible Electroporation, The NanoKnife System
Angiodynamics, Inc.
Prostate Cancer
08/24
08/24
Penshorn, Jennifer
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated
N/A
3
US
NanoTherm Ablation
MagForce USA
Prostate Cancer
07/23
07/23
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Recruiting
N/A
125
US, RoW
Robotic Waterjet Treatment, Aquablation therapy
PROCEPT BioRobotics
Benign Prostatic Hyperplasia, Localized Prostate Cancer
08/25
05/26
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Wright, Katie
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Gershman, Boris
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting
1/2
75
US
STM-416
SURGE Therapeutics
Non-muscle-invasive Bladder Cancer
12/25
12/25
NCT05918263: Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Recruiting
N/A
68
US
High-Intensity Interval Training Exercise Program
Dana-Farber Cancer Institute, Prostate Cancer Foundation
Prostate Cancer, Prostatic Neoplasms
03/26
03/27
Wlajnitz, Tina
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
Thai, Siline
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Preston, Mark
NCT03216525: Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Recruiting
3
136
US
Alvimopan, Entereg, Placebo
Brigham and Women's Hospital, Merck Sharp & Dohme LLC
Bladder Cancer
12/23
06/24
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
BRIDGE, NCT05538663: Intravesical BCG vs GEMDOCE in NMIBC

Recruiting
3
870
US
Gemcitabine, GEMZAR, Docetaxel, Taxotere, Bacillus Calmette Guerin, BCG
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Non-muscle-invasive Bladder Cancer
11/29
10/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
NCT05399004: Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

Completed
N/A
34
NA
Survey Administration
Mayo Clinic, National Cancer Institute (NCI)
Bladder Carcinoma
06/24
06/24
NCT05918263: Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Recruiting
N/A
68
US
High-Intensity Interval Training Exercise Program
Dana-Farber Cancer Institute, Prostate Cancer Foundation
Prostate Cancer, Prostatic Neoplasms
03/26
03/27
Kates, Max
NCT05024773 / 2022-001236-28: Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Recruiting
3
112
Europe, US
ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Fidia Farmaceutici s.p.a.
Bladder Carcinoma in Situ (CIS)
11/25
11/27
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
GEMDOCE, NCT04386746: Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

Active, not recruiting
2
27
US
Gemcitabine, Gemzar, Docetaxel, Taxotere
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Carcinoma Bladder, Bladder Cancer
10/22
11/25
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1
51
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
NCT05399004: Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer

Completed
N/A
34
NA
Survey Administration
Mayo Clinic, National Cancer Institute (NCI)
Bladder Carcinoma
06/24
06/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Dickstein, Rian
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1
24
US
ZH9
Prokarium Ltd
NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
06/25
07/27
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
uTRACT, NCT05874921: Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Recruiting
N/A
400
US
Jelmyto (mitomycin) for pyelocalyceal solution, Jelmyto, UGN-101
UroGen Pharma Ltd.
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
04/26
01/28
Mazzarella, Brian
ARID II, NCT06873581: Pivotal Study of Voro Urologic Scaffold

Recruiting
3
266
US
Voro Urologic Scaffold
Levee Medical, Inc.
Radical Prostatectomy, Stress Urinary Incontinence (SUI)
02/27
02/27
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated
N/A
3
US
NanoTherm Ablation
MagForce USA
Prostate Cancer
07/23
07/23
NCT05186740: ProVee Urethral Expander System IDE Study (ProVIDE)

Active, not recruiting
N/A
221
Europe, Canada, US
ProVee Urethral Expander System, ProVee Expander, ProVee, Urethral Access Sheath
ProVerum Medical
Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms
03/24
12/28
NCT06236802: ProVIDE II Bridging Study

Active, not recruiting
N/A
40
Europe, US
ProVee device, ProVee Expander, ProVee
ProVerum Medical
BPH With Symptomatic Lower Urinary Tract Symptoms
09/24
06/29
CLEAR, NCT04338776: Comparing UroLift Experience Against Rezūm

Active, not recruiting
N/A
120
Europe, US
UroLift, Rezum
NeoTract, Inc.
Benign Prostatic Hyperplasia
05/25
12/25
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Santoyo, Jose
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting
1/2
75
US
STM-416
SURGE Therapeutics
Non-muscle-invasive Bladder Cancer
12/25
12/25
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
RELIEF, NCT05512039: Reduced-dose Botox for Urgency Incontinence Among Elder Females

Recruiting
1/2
376
US
Botox 50 Unit Injection, OnabotulinumtoxinA 50 Unit Injection, Botox 100 Unit Injection, OnabotulinumtoxinA 100 Unit
Dartmouth-Hitchcock Medical Center, Patient-Centered Outcomes Research Institute, Dartmouth College, University of Alabama at Birmingham, University of Pittsburgh, University of Texas, Kaiser Permanente, Oregon Health and Science University, Stanford University, University of Connecticut, University of Nebraska
Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
09/26
01/27
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

Completed
N/A
121
US
Irreversible Electroporation, The NanoKnife System
Angiodynamics, Inc.
Prostate Cancer
08/24
08/24
Penshorn, Jennifer
NCT05010759: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Terminated
N/A
3
US
NanoTherm Ablation
MagForce USA
Prostate Cancer
07/23
07/23
NCT06051942: PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Recruiting
N/A
125
US, RoW
Robotic Waterjet Treatment, Aquablation therapy
PROCEPT BioRobotics
Benign Prostatic Hyperplasia, Localized Prostate Cancer
08/25
05/26
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Wright, Katie
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Gershman, Boris
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting
1/2
75
US
STM-416
SURGE Therapeutics
Non-muscle-invasive Bladder Cancer
12/25
12/25
NCT05918263: Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Recruiting
N/A
68
US
High-Intensity Interval Training Exercise Program
Dana-Farber Cancer Institute, Prostate Cancer Foundation
Prostate Cancer, Prostatic Neoplasms
03/26
03/27
Wlajnitz, Tina
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
Thai, Siline
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30

Download Options